🔗 Share this article

While the US undertakes unprecedented revisions to its vaccine schedules, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccines throughout the pandemic and has concentrated on potential fatalities following COVID-19 vaccination in her brief time at the FDA.

Planned Overhauls to Pediatric Immunization Program

Agency leaders had intended to unveil sweeping revisions to the pediatric vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with many the world with no evidence for benefit. This reveal has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric vaccine recommendations in the US to become more like the Danish model, a country with universal health coverage and a citizenry about the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Expertise

Høeg has no apparent experience in medication creation, regulation or administrative roles, which has been typical for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who headed the center have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and every single one have to be managed,” she said. “The thing you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant management element to the role, which manages over 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock added.

Response and Controversial Policies

Regarding concerns about Høeg’s qualifications and whether this appointment represents greater collaboration among FDA leaders on vaccines, a representative stated that the “concerns are based on inaccurate premises”.

“This background matches the responsibilities of her job,” the representative explained, pointing to the period Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a contentious expedited medication authorization process that reportedly worried her former heads. “By what process are these medications being selected for this voucher program? Who takes the choices?” Dr. Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Established Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if concerning, past, critics said. She published a research paper using non-validated crowd-sourced reports to assess the rate of heart inflammation after Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the current federal leadership included changing regulations for recently developed shots and halting “non-essential” immunizations, she said after the election on a online show. At the agency, Høeg has reportedly suggested preventing teenage boys from receiving Covid vaccinations.

“She’s an thorough true believer who starts off with her conclusions and reverse-engineers to retrofit the data in a highly disingenuous, untruthful fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg became part of other skeptics, {like|